HGH Fragment 176-191
Frag 176-191 · Lipolytic fragment
The unmodified GH fragment AOD-9604 was derived from — same lipolytic claim, weaker evidence.
Class
Human growth hormone C-terminal fragment
Half-life
~30 minutes
Evidence
Animal models
Animal models
Evidence comes primarily from rodent or other animal studies. Translation to humans is unproven.
Overview
HGH Fragment 176-191 is the native C-terminal fragment of human growth hormone that AOD-9604 was engineered from. It carries the same premise — the lipolytic activity of GH isolated from its growth-promoting effects — with less optimisation and considerably less human data.
Rodent studies from the 1990s showed reduced fat mass and increased lipolysis without the insulin resistance that full-length GH causes. That work is what launched the entire fragment category and led to AOD-9604's development.
Given that the more optimised derivative failed a properly powered human trial, the evidence base for the parent fragment producing meaningful human fat loss is weak. Its very short half-life also means any effect would require frequent dosing.
How it works
- Proposed direct stimulation of lipolysis in adipocytes and inhibition of lipogenesis.
- Does not bind the GH receptor; does not raise IGF-1 or blood glucose.
- Reported to increase beta-3 adrenergic receptor expression in adipose tissue in rodent models.
- Very short plasma half-life limits systemic exposure per dose.
What the research shows
Researched effects
- Reduced fat mass in obese rodent models without insulin resistance
- Increased in-vitro lipolysis in isolated adipocytes
- No controlled human efficacy trials at this fragment specifically
Limitations & what it won't do
- No published human efficacy trials for the unmodified fragment.
- Its optimised derivative (AOD-9604) failed a 536-person human trial for the same indication.
- WADA prohibited.
- Half-life under an hour makes once-daily protocols mechanistically questionable.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Commonly cited protocol (efficacy unsupported in humans)
250–500 mcgCommunity protocol only. Documented for reference; not supported by human efficacy data.
Reconstitution & measuring your dose
Handling
- Typical vial sizes
- 2 · 5 mg
- Suggested BAC water
- 2 mL
- Storage
- Lyophilised powder refrigerated at 2–8 °C, protected from light.
- After reconstitution
- Reconstituted: approximately 30 days refrigerated.
Why 2 mL? A 5 mg vial in 2 mL yields 2500 mcg/mL — 250 mcg lands on 10 units of a U-100 syringe.
Dose calculator
Draw to
10units
= 0.1 mL · 25 mcg per unit
Concentration
2500 mcg/mL
Doses per vial
20
Side effects
Common
- Injection-site irritation
- Occasional flushing
- Generally reported as well tolerated
Serious / rare
- No well-characterised serious effects, largely because human data is absent
Contraindications & interactions
Do not use if you have
- Pregnant, breastfeeding, or trying to conceive
No pregnancy safety data.
Use caution if you have
- Active cancer or current oncology treatment
Growth-factor-adjacent compound; obtain oncology clearance.
What to monitor
- Body composition, with realistic expectations given the evidence base
Commonly combined with
References
- Ng FM et al. — Metabolic studies of a synthetic lipolytic domain of hGHHormone Research 2000;53:274-278
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if HGH Fragment 176-191 fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment